Eplerenone — Discount Pricing

Other medications in Heart & Cardiovascular

• Epoprostenol
• Eprosartan
• Evolocumab
• Ezetimibe
• Felodipine
• Fenofibrate
• Flecainide
• Fluvastatin

What Eplerenone is approved for (FDA label)

Eplerenone Tablets are an aldosterone antagonist indicated for: The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). 1.2 Hypertension Eplerenone Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and MI. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake.

Source: Read the full FDA label on DailyMed. Label effective date: August 28, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Eplerenone (FDA label)

25 mg tablets: yellowish red color diamond shaped biconvex film coated tablets, debossed with "E" on one side and "25" on other side 50 mg tablets: yellowish red color diamond shaped biconvex film coated tablets, debossed with "E" on one side and "50" on other side Tablets: 25 mg, 50 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 3a3047f2-0155-4a07-955f-839a312cf879. SPL document ID: 5a1e5d3d-eb1f-d60d-e063-6294a90a812f. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Eplerenone (FDA label)

The following adverse reactions are discussed in greater detail in other sections of the labeling: Hyperkalemia [see Warnings and Precautions (5.1) ] Hypertension: In clinical studies, adverse reactions with eplerenone were uncommon. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Breckenridge Pharmaceutical, Inc. at 1-800-367-3395 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. Hypertension Eplerenone has been evaluated for safety in 3091 patients treated for hypertension.

Source: FDA prescribing information (DailyMed). Set ID: 3a3047f2-0155-4a07-955f-839a312cf879. SPL document ID: 5a1e5d3d-eb1f-d60d-e063-6294a90a812f. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Eplerenone (FDA label)

For all patients: Serum potassium >5.5 mEq/L at initiation ( 4 ) Creatinine clearance ≤30 mL/min ( 4 ) Concomitant use with strong CYP3A inhibitors ( 4 , 7.1 ) For the treatment of hypertension: Type 2 diabetes with microalbuminuria ( 4 ) Serum creatinine >2.0 mg/dL in males, >1.8 mg/dL in females ( 4 ) Creatinine clearance <50 mL/min ( 4 ) Concomitant use of potassium supplements or potassium-sparing diuretics ( 4 ) For All Patients Eplerenone Tablets are contraindicated in all patients with: serum potassium >5.5 mEq/L at initiation, creatinine clearance ≤30 mL/min, or concomitant administration of strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir) [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ]. For Patients Treated for Hypertension Eplerenone Tablets are contraindicated for the treatment of hypertension in patients with: type 2 diabetes with microalbuminuria, serum creatinine >2.0 mg/dL in males or >1.8

Source: FDA prescribing information (DailyMed). Set ID: 3a3047f2-0155-4a07-955f-839a312cf879. SPL document ID: 5a1e5d3d-eb1f-d60d-e063-6294a90a812f. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Eplerenone (FDA label)

Hyperkalemia: Patients with decreased renal function, diabetes, proteinuria or patients who are taking ARBs, NSAIDs or moderate CYP3A inhibitors are at increased risk. Monitor serum potassium levels and adjust dose as needed. ( 5.1 ) 5.1 Hyperkalemia The risk of hyperkalemia is higher in patients with impaired renal function, proteinuria, diabetes and those concomitantly treated with ARBs, NSAIDs and moderate CYP3A inhibitors. Minimize the risk of hyperkalemia with proper patient selection and monitoring. [see Dosage and Administration (2) , Contraindications (4) , Adverse Reactions (6.2) , and Drug Interactions (7) ]. Monitor patients for the development of hyperkalemia until the effect of eplerenone is established. Patients who develop hyperkalemia (5.5-5.9 mEq/L) may continue eplerenone therapy with proper dose adjustment. Dose reduction decreases potassium levels. Patients on moderate CYP3A inhibitors that cannot be avoided should have their dose of eplerenone reduced. [see Drug Interactions (7.2) ].

Source: FDA prescribing information (DailyMed). Set ID: 3a3047f2-0155-4a07-955f-839a312cf879. SPL document ID: 5a1e5d3d-eb1f-d60d-e063-6294a90a812f. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Eplerenone (FDA label)

CYP3A Inhibitors: In patients with hypertension initiate at 25 mg once daily. For inadequate blood pressure response, dosing may be increased to a maximum of 25 mg twice daily. ( 2.4 , 7.1 , 12.3 ) 7.1 CYP3A Inhibitors Eplerenone metabolism is predominantly mediated via CYP3A. Do not use eplerenone with drugs that are strong inhibitors of CYP3A [see Contraindications (4) and Clinical Pharmacology (12.3) ]. In patients with hypertension taking a moderate CYP3A inhibitor, initiate at 25 mg once daily.

Source: FDA prescribing information (DailyMed). Set ID: 3a3047f2-0155-4a07-955f-839a312cf879. SPL document ID: 5a1e5d3d-eb1f-d60d-e063-6294a90a812f. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.